Coherus BioSciences Inc.

(CHRS) Follow Trade

Research

By |

Chart Analyst Filings Earnings Financials News Dividends

Profile

Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.

Contact Information

Website:	www.coherus.com
Email:	darrington@coherus.com
Main Phone:	+1 650 649-3530
Address:	333 Twin Dolphin Drive
Address 2:	Suite 600
State:	CA
City / Town:	Redwood City
Country:	US
Postal Code:	94065

Issuer Information

Exchange:	NSD
CEO:	Dennis M. Lanfear
Employees:	306
NAICS:	Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

Profile

Contact Information

Website:	www.coherus.com
Email:	darrington@coherus.com
Main Phone:	+1 650 649-3530
Address:	333 Twin Dolphin Drive
Address 2:	Suite 600
State:	CA
City / Town:	Redwood City
Country:	US
Postal Code:	94065

Issuer Information

Exchange:	NSD
CEO:	Dennis M. Lanfear
Employees:	306
NAICS:	Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

$ 15.73 $ -0.29 (-1.81%)

Last Price 15.73	Change $ -0.29	Change % -1.81	Tick N/A
Bid 15.83	Bid Size 100.00	Ask 16.15	Ask Size 100.00
Open 15.99	High 16.23	Low 15.60	Prev Close 16.02
Last Trade Mar/02 - 16:00	Volume 3.9 mi	52 Wk Hi 22.22	52 Wk Low 10.87
Market Cap 1.1 bi	Ex-Div Date N/A	Div Rate N/A	Yield N/A
Shares 72,793,660.00	EPS (TTM) 1.61	PE Ratio 10.00	Exchange NSD

	Last 3 Mo	Last 12 Mo
Number of Insider Trades	1	8
Number of Buys	0	5
Number of Sells	1	3
Net Activity	-20984	3085

Last 10 Buys	Shares
N/A	0

Last 10 Sell	Shares
Dennis M. Lanfear	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000
Alan C. Herman	1,000

	Current	1 Week Ago	2 Weeks Ago	3 Weeks Ago
High Target Price Estimate	45	45	45	45
Low Target Price Estimate	22	22	22	22
Mean Target Price Estimate	28.4	28.4	28.4	28.4
Standard Deviation	9.61	9.61	9.61	9.61
Date of Most Recent Estimate	05/17/18	05/17/18	05/14/18	05/17/18

Form Type	Form Description	Pages	Date
S-8	Securities offered to employees under employee benefit plans	9	2018-06-14
8-K	Report of unscheduled material events or corporate changes.	3	2018-05-29
8-K	Report of unscheduled material events or corporate changes.	53	2018-05-25
424B5	Prospectus filed under Rule 424(b)(5)	64	2018-05-23
424B5	Prospectus filed under Rule 424(b)(5)	64	2018-05-21
4	Statement of changes in beneficial ownership of securities	1	2018-05-17
4	Statement of changes in beneficial ownership of securities	1	2018-05-16
8-K	Report of unscheduled material events or corporate changes.	5	2018-05-15
8-K	Report of unscheduled material events or corporate changes.	6	2018-05-14
4	Statement of changes in beneficial ownership of securities	1	2018-05-11

	Current	1 Month Ago	2 Months Ago	3 Months Ago
Strong Buy	5	5	6	6
Moderate Buy	0	0	0	0
Hold	0	0	0	0
Moderate Sell	0	0	0	0
Strong Sell	0	0	0	0
Mean Rec.	1	1	1	1

Coherus BioSciences Inc.

Profile

Contact Information

Issuer Information

Equities News

IPO Report: Coherus BioSciences (CHRS)

11 New IPOs Totalling $1.8 Billion for Week of November 3

Inflation Rose 1.7 Percent For Consumers in 2012

Profile

Contact Information

Issuer Information

Equities News

IPO Report: Coherus BioSciences (CHRS)

11 New IPOs Totalling $1.8 Billion for Week of November 3

Inflation Rose 1.7 Percent For Consumers in 2012

RELEASING NOV-25: Greenwich Economic Forum (Full Event Coverage)